TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29471329

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 525

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 525
Study: 28110628

Group type: EXPERIMENTAL
Intervention: Sublingual glyceryl trinitrate (800 µg)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 110
Study: 25703440

Group type: EXPERIMENTAL
Intervention: XR-NTX (Vivitrol®; Alkermes Inc.)
Number of subjects: 34

Group type: COMPARATOR
Intervention: No medication (control)
Number of subjects: 34
Study: 23652894

Group type: EXPERIMENTAL
Intervention: Emulsion with 8% SCA and liquid serum with 40% SCA
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 21849081

Group type: EXPERIMENTAL
Intervention: Chlorproguanil-dapsone-artesunate (CDA) 2/2.5/4 mg/kg given once daily for three days
Number of subjects: 2045

Group type: EXPERIMENTAL
Intervention: Chlorproguanil-dapsone 2/2.5 mg/kg given once daily for three days
Number of subjects: 2045

Group type: EXPERIMENTAL
Intervention: Six-dose artemether-lumefantrine
Number of subjects: 2045
Study: 19596586

Group type: EXPERIMENTAL
Intervention: pegfilgrastim primary prophylaxis (PP)
Number of subjects: 59

Group type: COMPARATOR
Intervention: secondary prophylaxis (SP)
Number of subjects: 59
Study: 17012630

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (Symbicort Turbuhaler) 160/4.5 microg as needed
Number of subjects: 92

Group type: COMPARATOR
Intervention: Formoterol (Oxis Turbuhaler) 4.5 microg as needed
Number of subjects: 92
Study: 15532809

Group type: EXPERIMENTAL
Intervention: Preoperative chemoradiation therapy (CRT)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 100
Study: 11128345

Group type: EXPERIMENTAL
Intervention: Nonremovable off-bearing fiberglass cast
Number of subjects: 50

Group type: COMPARATOR
Intervention: Cloth shoe with a rigid sole and unloading alkaform insole
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Patient acceptance score
Number of subjects: 50
Study: 9282968

Group type: EXPERIMENTAL
Intervention: Aflurax (1200 mg, two tablets four times daily for 4 weeks)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo (two tablets four times daily for 4 weeks)
Number of subjects: 65
Study: 8275907

Group type: COMPARATOR
Intervention: Schizophrenic group (N = 19)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Paranoid subgroup (N = 10)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Disorganized subgroup
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: S.A.P.S. global score
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Duration of hospitalization
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Paranoid subgroup vs Disorganized subgroup
Number of subjects: 19
Study: 2433098

Group type: EXPERIMENTAL
Intervention: Oral hydromorphone hydrochloride 2 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oral hydromorphone hydrochloride 4 mg
Number of subjects: 12
Study: 29332671

Group type: EXPERIMENTAL
Intervention: Actical accelerometer
Number of subjects: 50

Group type: COMPARATOR
Intervention: Actiwatch 2
Number of subjects: 50
Study: 28679555

Group type: EXPERIMENTAL
Intervention: Juice supplemented with 15 μg vitamin D3
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Biscuit supplemented with 15 μg vitamin D3
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Juice supplemented with 15 μg vitamin D2
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Biscuit supplemented with 15 μg vitamin D2
Number of subjects: 335

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 335
Study: 26165782

Group type: EXPERIMENTAL
Intervention: Training session and three emails about the colorectal cancer screening program
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 12
Study: 23043428

Group type: EXPERIMENTAL
Intervention: Racial/ethnic discrimination (any frequency)
Number of subjects: 2490

Group type: EXPERIMENTAL
Intervention: Racial/ethnic discrimination (frequent and disturbing)
Number of subjects: 2490

Group type: EXPERIMENTAL
Intervention: Racial/ethnic discrimination (at least occasional)
Number of subjects: 2490
Study: 21080844

Group type: EXPERIMENTAL
Intervention: Intracoronary autologous bone marrow cell transplantation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no cell treatment)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups (IGF-1 levels above or below median)
Number of subjects: 0
Study: 18227359

Group type: EXPERIMENTAL
Intervention: Tailored computer program for self-management goals for nutrition and physical activity, reviewed at each clinic visit
Number of subjects: 310

Group type: COMPARATOR
Intervention: Printed health education materials
Number of subjects: 310
Study: 16932286

Group type: COMPARATOR
Intervention: Alendronate and risedronate (oral nitrogen-containing bisphosphonates)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ibandronate (oral, once-monthly dose of 150 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous bisphosphonates (currently under investigation)
Number of subjects: 0
Study: 14966716

Group type: EXPERIMENTAL
Intervention: Home-based resistance exercise program (lower-extremity resistance training 3 times a week)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (maintained current level of physical activity)
Number of subjects: 29
Study: 11158415

Group type: EXPERIMENTAL
Intervention: Sandimmun Neoral with grapefruit juice
Number of subjects: 8

Group type: COMPARATOR
Intervention: Sandimmun Neoral with water
Number of subjects: 8
Study: 9550632

Group type: EXPERIMENTAL
Intervention: NG‐monomethyl‐L‐arginine (L‐NMMA, 3 mg/kg priming dose plus 3 mg/kg/h) for 3 hours
Number of subjects: 9
Study: 7914620

Group type: EXPERIMENTAL
Intervention: Predictive algorithm based on neonatal body measurements (head circumference ≤31 cm or chest circumference ≤30 cm)
Number of subjects: 843

Group type: COMPARATOR
Intervention: Validation group testing of the predictive algorithm
Number of subjects: 843
Study: 3276343

Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanate (Augmentin)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Amoxicillin
Number of subjects: 108
Study: 29344579

Group type: EXPERIMENTAL
Intervention: Bortezomib, Adriamycin, and dexamethasone followed by bortezomib maintenance after tandem autologous transplantation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vincristine, Adriamycin, and dexamethasone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bortezomib
Number of subjects: 0
Study: 28850790

Group type: EXPERIMENTAL
Intervention: Tailored program outreach messages containing content tailored to EHR-derived diabetes risk factors
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Communication from personal physicians
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Careful development of messages to mitigate concerns over privacy and authenticity
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Techniques to counteract the threatening nature of personalized risk communication
Number of subjects: 35
Study: 25850881

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Fimasartan 30 mg
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Fimasartan 60 mg
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Fimasartan 30 mg/Amlodipine 5 mg
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Fimasartan 30 mg/Amlodipine 10 mg
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Fimasartan 60 mg/Amlodipine 5 mg
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Fimasartan 60 mg/Amlodipine 10 mg
Number of subjects: 420
Study: 23932998

Group type: EXPERIMENTAL
Intervention: Verbal implementation intentions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual implementation intentions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined verbal-visual implementation intentions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no implementation intentions)
Number of subjects: 0
Study: 21242819

Group type: EXPERIMENTAL
Intervention: EPT (50 μg transdermal estradiol daily and 200 mg/d micronized progesterone for the first 14 days of each month; n = 21)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg daily; n = 17)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control (no treatment; n = 21)
Number of subjects: 59
Study: 18422829

Group type: EXPERIMENTAL
Intervention: Diamorphine treatment
Number of subjects: 515
Study: 16731125

Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 25

Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 25
Study: 12556778

Group type: EXPERIMENTAL
Intervention: Two-bite technique (4 specimens, 2 passages)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Single-bite technique (2 specimens)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Two-bite technique (first samples)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Two-bite technique (second samples)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Forceps without a spike
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Spiked forceps
Number of subjects: 16

Group type: COMPARATOR
Intervention: Two-bite technique vs. single-bite technique
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Three types of forceps
Number of subjects: 16
Study: 10686961

Group type: EXPERIMENTAL
Intervention: Procalcitonin (PCT)
Number of subjects: 436

Group type: COMPARATOR
Intervention: C-reactive protein (CRP)
Number of subjects: 436

Group type: COMPARATOR
Intervention: Interleukin-6 (IL-6)
Number of subjects: 436

Group type: COMPARATOR
Intervention: Interferon-alpha
Number of subjects: 436
Study: 9343463

Group type: EXPERIMENTAL
Intervention: EGb (120 mg/d)
Number of subjects: 309

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 309
Study: 8170559

Group type: EXPERIMENTAL
Intervention: sorbinil
Number of subjects: 497

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 497
Study: 3024689

Group type: EXPERIMENTAL
Intervention: Codeine 60 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Codeine 90 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Triprolidine 10 mg (active control)
Number of subjects: 6
Study: 29443533

Group type: EXPERIMENTAL
Intervention: Yoga exercise with nutritional guidance
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Yoga exercise alone
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Nutritional guidance alone
Number of subjects: 400

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 400
Study: 27261562

Group type: EXPERIMENTAL
Intervention: Transdiagnostic Cognitive Behaviour Therapy (TD‐CBT)
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Disorder-specific Cognitive Behaviour Therapy (DS‐CBT)
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Clinician-guided Cognitive Behaviour Therapy (CG‐CBT)
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Self-guided Cognitive Behaviour Therapy (SG‐CBT)
Number of subjects: 233
Study: 25173752

Group type: EXPERIMENTAL
Intervention: GLP-2 administration
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: GLP-2 administration 7 hours after a high-fat meal
Number of subjects: 6
Study: 21720440

Group type: EXPERIMENTAL
Intervention: 0.25 mg TE
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: 0.5 mg TE
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: 1.0 mg TE
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: 0.5 or 1.0 mg TE (Part 2)
Number of subjects: 158
Study: 20685494

Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal system (BTDS) 10 to 40 microg/h
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal system (BTDS)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 18435869

Group type: EXPERIMENTAL
Intervention: Affect-focused body psychotherapy (ABP)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Standard psychiatric out-patient treatment (Control)
Number of subjects: 43
Study: 15939681

Group type: EXPERIMENTAL
Intervention: GIK solution (300 g glucose + 50 IU crystallized insulin + 80 mEq potassium chloride in one liter solution)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (traditional treatment)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: GIK solution
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 81
Study: 12836501

Group type: EXPERIMENTAL
Intervention: Stabilization appliance
Number of subjects: 60

Group type: COMPARATOR
Intervention: Non-occlusal appliance
Number of subjects: 60
Study: 10870743

Group type: EXPERIMENTAL
Intervention: Carbamazepine (CBZ)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gabapentin (GBP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 0
Study: 8662400

Group type: EXPERIMENTAL
Intervention: Laparoscopic hernia repair
Number of subjects: 30

Group type: COMPARATOR
Intervention: Open hernia repair (Shouldice repair)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 1831015

Group type: EXPERIMENTAL
Intervention: Ondansetron (8 mg, n = 18)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (n = 18)
Number of subjects: 36
Study: 6137856

Group type: EXPERIMENTAL
Intervention: Alprazolam 1.5-3 mg per day
Number of subjects: 46

Group type: COMPARATOR
Intervention: Diazepam 15-30 mg per day
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 31863809

Group type: EXPERIMENTAL
Intervention: Hydrofluoric acid etching followed by silanization for polymer-infiltrated ceramic (PIC) and glass ceramic (VS)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Diamond bur + SBU for resin composite (RC)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: In situ aging
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Surface treatment
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: CFU/mL
Number of subjects: 300
Study: 30683137

Group type: EXPERIMENTAL
Intervention: Isoflurane (2 cycles of 1 MAC isoflurane administered 5 minutes prior to incision)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Propofol (3-5 mg/kg/h intravenous injection for the duration of surgery)
Number of subjects: 30
Study: 29460154

Group type: EXPERIMENTAL
Intervention: Two non-compression miniplates (Group I)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Single non-compression miniplate (Group II)
Number of subjects: 28
Study: 26361060

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 24129991

Group type: EXPERIMENTAL
Intervention: Small-sided games (SGG)
Number of subjects: 18

Group type: COMPARATOR
Intervention: High-intensity interval training (HIT)
Number of subjects: 18
Study: 22369558

Group type: EXPERIMENTAL
Intervention: Periosteal pedicle graft (PPG)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Subepithelial connective tissue graft (SCTG)
Number of subjects: 20
Study: 20667921

Group type: EXPERIMENTAL
Intervention: Kangaroo Mother Care (KMC) for at least 6 hours per day
Number of subjects: 110

Group type: COMPARATOR
Intervention: Standard care (incubator or open care system)
Number of subjects: 110
Study: 17430323

Group type: EXPERIMENTAL
Intervention: Intravenous tramadol, 1 mg/kg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Saline 0.9%, 2 ml
Number of subjects: 60
Study: 16015252

Group type: EXPERIMENTAL
Intervention: Child plasma selenium levels
Number of subjects: 610
Study: 12240567

Group type: EXPERIMENTAL
Intervention: Cancellous, slivered iliac bone grafts and stabilization with rush-pins used as intramedullary nails in 12 cases, in addition to plaster of paris casts.
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Cancellous, slivered iliac bone grafts
Number of subjects: 125

Group type: COMPARATOR
Intervention: Initial management with circular POP with windows for wound care or posterior slabs made of POP, Cramer‐wire, or wood at random.
Number of subjects: 125
Study: 10695457

Group type: COMPARATOR
Intervention: Single-coil, unipolar configuration (active can alone)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: High SVC coil position
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Low SVC coil position
Number of subjects: 27
Study: 9187591

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate 30 mmol (7.5 g) daily for 3 days
Number of subjects: 44

Group type: COMPARATOR
Intervention: Normal saline equivalent to magnesium sulfate
Number of subjects: 44
Study: 1328366

Group type: EXPERIMENTAL
Intervention: Dietary treatment based on weight reduction and sodium restriction
Number of subjects: 64

Group type: COMPARATOR
Intervention: Drug treatment using a stepped-care approach with atenolol as the drug of first choice
Number of subjects: 64
Study: 2866059

Group type: EXPERIMENTAL
Intervention: Inhaled sodium cromoglycate (SCG; 20 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Clemastine (0.5 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ketotifen (0.5 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Isotonic saline (0.9% NaCl) placebo
Number of subjects: 10
Study: 26067748

Group type: EXPERIMENTAL
Intervention: INICC multidimensional hand hygiene approach
Number of subjects: 13201

Group type: COMPARATOR
Intervention: Males
Number of subjects: 13201

Group type: COMPARATOR
Intervention: Females
Number of subjects: 13201

Group type: COMPARATOR
Intervention: Physicians
Number of subjects: 13201

Group type: COMPARATOR
Intervention: Nurses
Number of subjects: 13201

Group type: COMPARATOR
Intervention: Adult ICUs
Number of subjects: 13201

Group type: COMPARATOR
Intervention: Neonatal ICUs
Number of subjects: 13201
Study: 30463388

Group type: EXPERIMENTAL
Intervention: Standardized exercise intensity prescription (using heart rate reserve)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Individualized exercise intensity prescription (using ventilatory threshold)
Number of subjects: 38
Study: 26937863

Group type: COMPARATOR
Intervention: Normal saline (n = 6)
Number of subjects: 18

Group type: COMPARATOR
Intervention: 2-day stored transfusion (n = 6)
Number of subjects: 18

Group type: COMPARATOR
Intervention: 35-day stored transfusion (n = 6)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: All groups (Normal saline, 2-day stored, 35-day stored)
Number of subjects: 18
Study: 23766436

Group type: EXPERIMENTAL
Intervention: Retrospective proxy reports of well-being
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Participants' life satisfaction over the last year of life
Number of subjects: 164
Study: 23156846

Group type: EXPERIMENTAL
Intervention: 0.1% tacrolimus (FK‐506) eye ointment
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 2% cyclosporine eye drops
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Open treatment with 0.1% FK‐506 eye ointment
Number of subjects: 24
Study: 20692561

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 0.5% ophthalmic solution
Number of subjects: 50

Group type: COMPARATOR
Intervention: Besifloxacin 0.6% ophthalmic suspension
Number of subjects: 50
Study: 19167587

Group type: EXPERIMENTAL
Intervention: Rosiglitazone hydrochloride (test formulation)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Rosiglitazone maleate (reference formulation)
Number of subjects: 20
Study: 15695780

Group type: EXPERIMENTAL
Intervention: Striatal dopamine transporter (DAT) imaging using (99m)Tc‐TRODAT‐1
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Striatal dopamine transporter (DAT) imaging in PD patients
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Striatal dopamine transporter (DAT) imaging in less severe PD patients
Number of subjects: 76

Group type: COMPARATOR
Intervention: Striatal dopamine transporter (DAT) imaging in controls
Number of subjects: 76
Study: 14508308

Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg intravenous M6G
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 0.13 mg/kg intravenous morphine
Number of subjects: 9

Group type: COMPARATOR
Intervention: Intravenous placebo
Number of subjects: 9
Study: 10499751

Group type: EXPERIMENTAL
Intervention: Group I: 2% plain lidocaine and 0.5% bupivacaine with epinephrine 1:200,000
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Group II: 1% plain lidocaine and 0.25% bupivacaine with epinephrine 1:200,000
Number of subjects: 360

Group type: EXPERIMENTAL
Intervention: Group III: 1.5% plain lidocaine and 0.37% bupivacaine with epinephrine 1:200,000
Number of subjects: 360
Study: 8973852

Group type: EXPERIMENTAL
Intervention: Chemotherapy after the first trimester of pregnancy
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Pregnancy
Number of subjects: 28

Group type: COMPARATOR
Intervention: Overall survival
Number of subjects: 28

Group type: COMPARATOR
Intervention: Relapse-free survival
Number of subjects: 28
Study: 1866057

Group type: EXPERIMENTAL
Intervention: A‐HDF (1.75 mmol/l calcium)
Number of subjects: 0

Group type: COMPARATOR
Intervention: B‐HDF (bicarbonate-containing and calcium-free)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: B2‐HDF (bicarbonate-containing and calcium-free with increased ultrafiltration rate)
Number of subjects: 0
Study: 30081854

Group type: EXPERIMENTAL
Intervention: Taurolidine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 25732606

Group type: EXPERIMENTAL
Intervention: Peer-led educational prevention measure
Number of subjects: 738

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 738
Study: 25509255

Group type: EXPERIMENTAL
Intervention: Shuxuening Injection (SI) 15 mL, twice daily for 14 days
Number of subjects: 91

Group type: COMPARATOR
Intervention: Routine treatment (Control group)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Shuxuening Injection (SI)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Healthy control group (20 healthy subjects)
Number of subjects: 91
Study: 22721575

Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 1005

Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1005

Group type: EXPERIMENTAL
Intervention: PCI
Number of subjects: 1005

Group type: COMPARATOR
Intervention: CABG
Number of subjects: 1005